Fred Aslan Sells 25,500 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Key Points

• CEO Fred Aslan sold 25,500 shares of Artiva Biotherapeutics at an average price of $6.00, amounting to a total transaction of $153,000, which decreased his ownership by 6.67%.
• Following significant sales, Artiva Biotherapeutics shares experienced a notable price increase, closing at $6.01 with a trading volume far exceeding its average.
• Analysts have varying opinions on the stock, with Wedbush raising the price target to $23.00 while Weiss Ratings maintains a "sell" rating, reflecting a consensus rating of "Moderate Buy."

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 25,500 shares of the stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $6.00, for a total transaction of $153,000.00. Following the sale, the chief executive officer owned 356,721 shares in the company, valued at approximately $2,140,326. This trade represents a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Fred Aslan also recently made the following trade(s):

• On Friday, August 15th, Fred Aslan sold 25,500 shares of Artiva Biotherapeutics stock. The shares were sold at an average price of $2.73, for a total transaction of $69,615.00.

Artiva Biotherapeutics Price Performance

Shares of ARTV traded up $3.24 during midday trading on Friday, reaching $6.01. The stock had a trading volume of 99,975,682 shares, compared to its average volume of 1,188,318. Artiva Biotherapeutics, Inc. has a 1-year low of $1.47 and a 1-year high of $15.49. The company's fifty day simple moving average is $2.91 and its two-hundred day simple moving average is $2.44.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.03). Equities analysts forecast that Artiva Biotherapeutics, Inc. will post -4.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. grew its position in Artiva Biotherapeutics by 26.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company's stock worth $165,000 after purchasing an additional 11,355 shares during the last quarter. Marshall Wace LLP purchased a new position in Artiva Biotherapeutics during the 2nd quarter worth $79,000. Nuveen LLC purchased a new position in Artiva Biotherapeutics during the 1st quarter worth $144,000. Jane Street Group LLC purchased a new position in Artiva Biotherapeutics during the 2nd quarter worth $67,000. Finally, Qube Research & Technologies Ltd purchased a new position in Artiva Biotherapeutics during the 2nd quarter worth $58,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings restated a "sell (e+)" rating on shares of Artiva Biotherapeutics in a report on Wednesday, October 8th. Wedbush raised their price objective on shares of Artiva Biotherapeutics from $18.00 to $23.00 and gave the company an "outperform" rating in a report on Friday. Finally, Needham & Company LLC restated a "buy" rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a report on Friday. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $18.25.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.